Aprea Therapeutics is focused on the development of novel therapeutic agents that induce p53-mediated cancer cell death by restoring normal function to mutated p53. Our lead candidate, APR-246, is a small molecule that binds, refolds and stabilizes mutant p53 and defective native p53 so that they may carry out the critical protective functions of normal p53.

Therapeutic rescue of dysfunctional p53 provides important advantages:

  • Tumor suppression activity is restored in cancer cells, allowing for rapid and efficient elimination of tumor burden
  • Activity and function of normal p53 is not impacted, thereby minimizing effects on healthy cells
  • Tumor cells are sensitized to standard chemotherapy and other therapeutic agents, boosting efficacy and potentially overcoming resistance
  • The mechanism of action is relevant in multiple tumor types and therapeutic benefit can be achieved in many different cancers

We have conducted extensive preclinical research on APR-246 in support of continued development.

Learn More

Several Phase I clinical studies with APR-246 have been completed and a Phase II study is underway.

Learn More